Veru Inc. (VERU)Healthcare | Biotechnology | Miami, United States | NasdaqCM
2.44 USD
+0.31
(14.554%)
⇧
(Oct. 15, 2026, 4 p.m.
EDT)
After hours: 2.39 -0.05 (-0.054%) ⇩ (Oct. 15, 2026, 5:43 p.m. EDT) |
Hot Take ↕ | Oct. 10, 2026, 10:44 a.m. EDT
The recent 160% surge following the Novo Nordisk supply deal announcement has created a volatile environment where the market is trying to price in the reality of the clinical trial results versus the hype. While the analyst consensus is overwhelmingly bullish with a mean target of $25.67, the fundamental data tells a different story: the company is burning cash, has negative earnings, and has suffered a catastrophic 67% decline in share price over the last nine years. The long-term trajectory is clearly broken, with three consecutive years of negative returns ending the window. Short-term, the stock is stuck in a tug-of-war. The options chain shows aggressive speculation on a further breakout to $6-$7, but the heavier put volume suggests smart money is hedging against a failure to deliver on the interim 2027 data or a regulatory hurdle. The statistical forecast model offers almost no guidance, reflecting the noise inherent in such a low-priced, biotech stock. Until the Phase 2b PLATEAU trial data is released and proven successful, the business quality remains unproven, and the balance sheet is deteriorating. This is a high-risk speculative play on a specific catalyst, not a sound investment in the underlying company. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.134480 |
| AutoARIMA | 0.134483 |
| MSTL | 0.140059 |
| AutoTheta | 0.196183 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 39% |
| H-stat | 0.55 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.309 |
| Excess Kurtosis | -0.96 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Ex Dividend Date | 2014-04-27 |
| Last Dividend Date | 2014-04-27 |
| Debt to Equity Ratio | 9.455 |
| Market Cap | 41,602,780 |
| Forward P/E | -2.44 |
| Beta | -1.20 |
| Website | https://verupharma.com |
As of Oct. 10, 2026, 10:44 a.m. EDT: Speculators are positioning for a binary event rather than steady appreciation. Call volume is heavily skewed toward out-of-the-money strikes ($6.00 and $7.00) expiring in late October, suggesting a bet on a massive gap-up driven by the Novo Nordisk supply deal. However, put volume is significantly higher than call volume across longer-dated horizons (January and April 2027), with heavy open interest at the $3.00 strike. This indicates a 'long gamma' strategy where traders are selling volatility expecting the stock to remain range-bound or decline, despite the recent surge.
| Date | Dividend | Yield % |
|---|---|---|
| 2014-04-28 | 0.7 | 0.932091 |
| 2014-01-27 | 0.7 | 0.877193 |
| 2013-10-28 | 0.7 | 0.705645 |
| 2013-07-29 | 0.7 | 0.767544 |
| 2013-04-29 | 0.7 | 0.904393 |
| 2013-01-28 | 0.6 | 0.774194 |
| 2012-10-31 | 0.6 | 0.857143 |
| 2012-07-30 | 0.6 | 1.039861 |
| 2012-04-30 | 0.6 | 0.998336 |
| 2012-01-30 | 0.5 | 0.959693 |
| 2011-10-31 | 0.5 | 1.098901 |
| 2011-07-29 | 0.5 | 1.084599 |
| 2011-04-29 | 0.5 | 1.057082 |
| 2011-01-27 | 0.5 | 0.924214 |
| 2010-11-01 | 0.5 | 0.909091 |
| 2010-08-02 | 0.5 | 0.990099 |
| 2010-04-21 | 0.5 | 0.740741 |
| 2010-01-27 | 0.5 | 0.924214 |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.40632606 |
| Address1 | 2,916 North Miami Avenue |
| Address2 | Suite 1000 |
| All Time High | 245.7 |
| All Time Low | 2.05 |
| Ask | 3.32 |
| Ask Size | 2 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 322,510 |
| Average Daily Volume3 Month | 236,465 |
| Average Volume | 236,465 |
| Average Volume10Days | 322,510 |
| Beta | -1.196 |
| Bid | 1.88 |
| Bid Size | 2 |
| Book Value | 1.664 |
| City | Miami |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.44 |
| Current Ratio | 4.423 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 2.47 |
| Day Low | 2.12 |
| Debt To Equity | 9.455 |
| Display Name | Veru |
| Dividend Date | 1,399,420,800 |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,786,363,200 |
| Earnings Call Timestamp Start | 1,786,363,200 |
| Earnings Timestamp | 1,786,365,000 |
| Earnings Timestamp End | 1,786,365,000 |
| Earnings Timestamp Start | 1,786,365,000 |
| Ebitda | -27,702,872 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.67 |
| Enterprise Value | 18,548,144 |
| Eps Current Year | -0.87 |
| Eps Forward | -1.0 |
| Eps Trailing Twelve Months | -0.61 |
| Esg Populated | 0 |
| Ex Dividend Date | 1,398,643,200 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.5406 |
| Fifty Day Average Change | -0.100600004 |
| Fifty Day Average Change Percent | -0.039596945 |
| Fifty Two Week Change Percent | -40.632607 |
| Fifty Two Week High | 7.33 |
| Fifty Two Week High Change | -4.89 |
| Fifty Two Week High Change Percent | -0.6671214 |
| Fifty Two Week Low | 2.05 |
| Fifty Two Week Low Change | 0.3900001 |
| Fifty Two Week Low Change Percent | 0.19024396 |
| Fifty Two Week Range | 2.05 - 7.33 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 918,743,400,000 |
| Five Year Avg Dividend Yield | 3.58 |
| Float Shares | 15,478,451 |
| Forward Eps | -1.0 |
| Forward P E | -2.44 |
| Free Cashflow | -14,444,403 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 20 |
| Fullday Change | 0.30999994 |
| Fullday Change Percent | 14.553987 |
| Fullday Price | 2.44 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.09219 |
| Held Percent Institutions | 0.19641 |
| Implied Shares Outstanding | 17,050,320 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Dividend Date | 1,398,643,200 |
| Last Dividend Value | 0.7 |
| Last Fiscal Year End | 1,759,190,400 |
| Last Split Date | 1,754,870,400 |
| Last Split Factor | 1:10 |
| Long Business Summary | Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and internationally. It provides FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company develops enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, an oral selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida. |
| Long Name | Veru Inc. |
| Market | us_market |
| Market Cap | 41,602,780 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_316215 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -14,109,339 |
| Next Fiscal Year End | 1,790,726,400 |
| Non Diluted Market Cap | 41,943,787 |
| Number Of Analyst Opinions | 3 |
| Open | 2.14 |
| Operating Cashflow | -26,042,992 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Peg Ratio | 3.6 |
| Phone | 305 509 6897 |
| Post Market Change | -0.05430007 |
| Post Market Change Percent | -2.2254126 |
| Post Market Price | 2.3857 |
| Post Market Time | 1,792,100,629 |
| Previous Close | 2.13 |
| Price Eps Current Year | -2.8045979 |
| Price Hint | 4 |
| Price To Book | 1.4663461 |
| Profit Margins | 0.0 |
| Quick Ratio | 4.181 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | 0.31 |
| Regular Market Change Percent | 14.554 |
| Regular Market Day High | 2.47 |
| Regular Market Day Low | 2.12 |
| Regular Market Day Range | 2.12 - 2.47 |
| Regular Market Open | 2.14 |
| Regular Market Previous Close | 2.13 |
| Regular Market Price | 2.44 |
| Regular Market Time | 1,792,094,400 |
| Regular Market Volume | 505,125 |
| Return On Assets | -0.54026 |
| Return On Equity | -0.64542997 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 17,050,320 |
| Shares Percent Shares Out | 0.08229999 |
| Shares Short | 1,402,996 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 1,347,868 |
| Short Name | Veru Inc. |
| Short Percent Of Float | 0.09060001 |
| Short Ratio | 6.9 |
| Source Interval | 15 |
| State | FL |
| Symbol | VERU |
| Target High Price | 28.0 |
| Target Low Price | 24.0 |
| Target Mean Price | 25.66667 |
| Target Median Price | 25.0 |
| Total Cash | 25,737,528 |
| Total Cash Per Share | 1.51 |
| Total Debt | 2,682,892 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.61 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.49725 |
| Two Hundred Day Average Change | -0.057250023 |
| Two Hundred Day Average Change Percent | -0.022925226 |
| Type Disp | Equity |
| Volume | 505,125 |
| Website | https://verupharma.com |
| Zip | 33,127 |